Biomarker ID | 813 |
PMID | 22113713 |
Year | 2012 |
Biomarker | TGFβ1 (transforming growth factor beta 1) |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Associated with Prostate cancer specific Survival |
Odds Ratio/Hazard Ratio/Relative Risk | HR: 10.4 (95% CI: 2.01–52.00) |
Effect on Pathways | Pathways Include:-TGF-beta receptor activation of SMADs,NF-kappaB activation by non-typeable Hemophilus influenzae,Cell cycle: G1/S checkpoint, Syndecan 2 pathway,Signal transduction through IL-1R |
Experiment | disease specific survival Vs no survival |
Type of Biomarker | Prognostic |
Cohort | 44 patients with prostate cancer who ubderwent radical prosteactomy were chosen for the study. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p=0.0 |
Method Used | qRT-PCR |
Clinical | No |
Remarks | Multivariate model considering Gleason Score, PSA, TGFb1 and IL-7. log-transformed expressions were used |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | TGFB1 |